Gerresheimer AG, the Germany-based drug packaging company, said it is laying off 140 workers and shuttering its Millville, NJ, glass operation this summer.
German pharmaceutical giant Bayer said it expects to spend $3.4 million to expand its Indonesian production capacity for effervescents this year.
Gilead Sciences said it's investing an additional $100 million to expand its operations in Edmonton, Canada.
Canada's Medicago, a biotech that is using plant technology to manufacture vaccines against Ebola and other viruses, will build a $200 million manufacturing facility in Quebec City. The company is getting substantial support from taxpayers but says when complete, it will more than double its workforce there.
A joint venture between Malaysia's Pharmaniaga and Saudi Arabia-based Modern Healthcare Solutions to build a pharma plant in Saudi Arabia appears unlikely to make it to the finish line.
In a virtuous cycle, Johnson & Johnson is kicking in some more funding for continous manufacturing research by Rutgers University, whose engineers are helping J&J's Janssen unit transition some products to the new technology at a plant in Puerto Rico.
Having laid out plans last fall to expand a biologics plant in the U.S., AstraZeneca is now planning to build a new large-molecule filling facility in Sweden, adding up to 250 jobs in the process. The U.K. drugmaker says the new facility is part of a bigger plan for its biologics manufacturing, the details of which it will announce later.
Patheon has been on an M&A blitz, buying up specialty manufacturers that can help it broaden its network as it muscles up as a global CDMO. But the North Carolina-based company is unafraid to shed assets that no longer fit that blueprint and so is selling a plant in Mexico to over-the-counter king Perrigo.
Hikma, which picked up Boehringer Ingelheim's massive manufacturing facility in Bedford, OH last year, has started stripping out the usable equipment and installing it in some of its other plants as its prepares to build its sterile injectable capacity.
U.S. drugmaker Alexion will build its first biologics plant outside the U.S. in Ireland, spending more than $500 million and adding 200 jobs when it is operational in 2019. The facility will be at a site in Dublin where the maker of rare disease drug Soliris is already erecting a logistics operation.